Gilenya (Fingolimod)

This is a medicine used to treat a condition called multiple sclerosis. It helps control the symptoms by stopping certain immune cells from moving to the brain and spinal cord. It's taken as a pill.

Brand names:Gilenya
Medication

What people taking Gilenya (Fingolimod) report

Every report comes from a Lived member, sent anonymously.

Have you tried Gilenya (Fingolimod) for Relapsing-Remitting Multiple Sclerosis?

NameHow it went

About Gilenya (Fingolimod)

What It's For

Fingolimod, sold as Gilenya and as generic capsules, is a daily oral medicine for relapsing forms of multiple sclerosis (MS). MS is a disease in which the immune system attacks the protective coating around nerves in the brain and spinal cord, causing episodes of symptoms such as numbness, weakness, vision problems or trouble with balance. Fingolimod is a disease-modifying therapy: it does not treat a flare as it happens, but lowers the chance of new ones over time. It is approved for adults and children 10 and older with clinically isolated syndrome (a first MS-like episode), relapsing-remitting MS, and secondary progressive MS that is still active with relapses or new inflammation on scans. It is not approved for primary progressive MS. Tascenso ODT (orally disintegrating tablet) is another brand of fingolimod, made as a tablet that dissolves on the tongue, for people who find capsules hard to swallow. In a two-year study of adults with relapsing-remitting MS, people taking fingolimod had fewer than half as many relapses as those on a placebo (an inactive pill), and 70% stayed relapse-free compared with 46%. It also slowed disability that persisted for at least three months, and reduced new areas of inflammation on magnetic resonance imaging (MRI) brain scans. Compared with a weekly interferon injection, an older MS treatment, it roughly halved the relapse rate over one year. Several other oral, injected and infused MS medicines now exist, so the choice usually involves weighing its monitoring needs and risks against alternatives with a neurologist.

How It Works

In MS, certain white blood cells called lymphocytes travel from the lymph nodes into the brain and spinal cord, where they drive the inflammation that damages nerves. Lymphocytes rely on a signaling molecule called sphingosine 1-phosphate (S1P) to know when to leave the lymph nodes. The body converts fingolimod into an active form that attaches to S1P receptors on lymphocytes and effectively traps many of them inside the lymph nodes. The number of lymphocytes circulating in the blood drops to roughly a quarter of its usual level, and fewer can reach the nervous system. Exactly how this produces the benefit in MS is not fully known. The cells are held back rather than destroyed, which is why counts recover within one to two months after stopping. Fingolimod's effects are not limited to immune cells. It also has distinctive effects elsewhere in the body, including a slower heart rate at the start of treatment and a small risk of swelling at the back of the eye.

Dosage & Administration

Fingolimod is taken once a day, with or without food. Adults and children who weigh more than 40 kilograms (about 88 pounds) take 0.5 milligrams; children 10 and older who weigh 40 kilograms or less take 0.25 milligrams. Higher doses add side effects without adding benefit. Gilenya and generic versions are swallowed as capsules. Tascenso ODT is placed on the tongue and allowed to dissolve before swallowing, with or without water. The first dose is given in a clinic or other setting that can manage a slow heartbeat. Staff take an electrocardiogram (ECG, a recording of the heart's electrical rhythm) before the dose, check pulse and blood pressure every hour for at least 6 hours, and repeat the ECG at the end. Some people, such as those with certain heart conditions or who take medicines that slow the heart, are monitored overnight. Before that first dose, the care team also reviews a recent blood count, liver tests, an eye exam, a skin check and immunity to chickenpox. Taking it every day matters more than with many medicines, because a break can make the heart-rate effect return. Missing a dose for one day or more in the first two weeks, more than seven days in weeks three and four, or more than 14 days after the first month means the next dose needs the same supervised monitoring as the first. If doses are missed, contact the prescriber before restarting.

Side Effects

The most common side effects in studies were headache, diarrhea, cough, back pain, flu and sinus infections, and a rise in liver enzymes found on blood tests. Blood pressure also tends to rise slightly, so it is checked during treatment. The heart rate usually drops within an hour of the first dose, is lowest around 6 hours later, and returns to its normal level within about a month. Most people feel nothing, but some notice dizziness, tiredness, a pounding or slow heartbeat, or chest discomfort, usually within the first day. Report these to the care team, including after you go home. Because it lowers the number of circulating immune cells, fingolimod raises the risk of infections, including shingles, herpes infections and, rarely, life-threatening infections such as cryptococcal meningitis (a fungal infection of the lining of the brain). This risk lasts for up to two months after stopping. Fever or other signs of infection should be reported promptly. A rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) has also occurred, mostly after 18 months or more of treatment. It shows up as weakness on one side of the body, clumsiness, vision trouble, or changes in thinking and memory that build over days to weeks, and should be reported to the care team right away. Other important risks have warning signs worth knowing. Macular edema (fluid swelling at the center of the retina, at the back of the eye) can blur vision, mostly in the first three to four months, and is more likely in people with diabetes or a history of uveitis (eye inflammation). Liver injury is uncommon but can be serious; unexplained nausea, pain in the upper right abdomen, dark urine or yellowing of the skin or eyes should be reported promptly. New or worsening shortness of breath also warrants a call. Rarely, fingolimod causes a brain swelling condition called posterior reversible encephalopathy syndrome (PRES); a sudden severe headache, confusion, sudden vision changes or a seizure need immediate medical attention. The risk of some skin cancers, mainly basal cell carcinoma and melanoma, is higher, so a new or changing skin spot should be checked; lymphoma has also been reported.

Interactions & Warnings

Fingolimod is not used in people who, in the past six months, have had a heart attack, unstable angina, a stroke or a transient ischemic attack (a brief stroke-like episode), or who have serious heart failure. It is also avoided with certain types of heart block unless a pacemaker is in place, an ECG showing a markedly prolonged QT interval (a delay in the heart's electrical recovery between beats), or heart rhythm medicines such as amiodarone or sotalol. Medicines that slow the heart, including beta blockers, digoxin, diltiazem and verapamil, can deepen the heart-rate drop at the start; the prescriber may ask whether they can be switched beforehand, or arrange overnight monitoring. Other medicines that suppress the immune system, including steroids, cancer treatments and some previous MS therapies, add to the infection risk, so the timing of a switch from another MS medicine is planned carefully. Live vaccines (vaccines made with a weakened form of the germ) should be avoided during treatment and for two months after stopping, and other vaccines may work less well. People who have never had chickenpox or its vaccine are usually vaccinated first and wait a month before starting. Fingolimod can harm a developing baby; registry data show more major birth defects with its use. Anyone who could become pregnant should use effective contraception during treatment and for two months after the last dose, because the drug takes that long to leave the body. Tell the prescriber about a pregnancy, or plans for one, so MS treatment can be adjusted. Do not stop fingolimod without talking to the prescriber. Some people have had a severe increase in disability, with many new lesions on MRI, after stopping, usually within 12 weeks, and most did not fully recover their previous level of function.

What to Expect

After the supervised first dose, most people take fingolimod at home with little day-to-day disruption. Its effect on the immune system begins quickly, but its value is measured over months and years: fewer relapses and fewer new lesions on MRI scans. A relapse can still happen during treatment and does not necessarily mean the medicine has failed; the neurologist looks at the overall pattern. Monitoring is a real part of treatment. Expect an eye exam three to four months after starting and any time vision changes, regular blood tests for liver function and blood counts, blood pressure checks, periodic skin checks, and routine MRI scans. Sun protection is sensible because of the skin cancer risk, and routine cancer screening, such as cervical screening, should stay up to date. Fingolimod is usually a long-term treatment, but it is not necessarily lifelong. People may change medicines because of side effects, disease activity, pregnancy plans or longer-term infection risk. Stopping or switching is planned with the neurologist, with a clear plan for what comes next and when. During the months after stopping, new or worsening MS symptoms should be reported to the care team promptly.

Questions to Ask Your Doctor

  1. 1.Why is fingolimod a good fit for my type of MS compared with the newer oral medicines or infusions?
  2. 2.Where will my first dose be given, and will my heart conditions or current medicines mean overnight monitoring?
  3. 3.Which tests and eye or skin exams will I need, and how often?
  4. 4.What should I do if I miss doses, and when would I need monitored dosing again?
  5. 5.If I want to become pregnant or need to stop fingolimod, what is the plan to protect me from a rebound in MS activity?

Last reviewed • Oct 2026

Educational content, not medical advice.